← All trials
NCT06092606
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 4, 2023
- Primary completion
- Jan 31, 2025
- Completion date
- Jan 31, 2025
- First posted
- Oct 23, 2023
- Last posted
- Oct 23, 2023
- Enrollment
- 90
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ChinaLead sponsor
- Henan Medical UniversityOverall official - principal investigator
- Central South UniversityOverall official - principal investigator
- Peking UniversityOverall official - principal investigator
- Peking UniversityOverall official - principal investigator
- Zhejiang UniversityOverall official - principal investigator
- Dalian Medical UniversityOverall official - principal investigator
- Zhengzhou UniversityOverall official - principal investigator
- Kunming Medical UniversityOverall official - principal investigator
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Central South UniversityOfficial
- Zhengzhou UniversityOfficial
- Kunming Medical UniversityOfficial
- Chinese Academy of Medical SciencesOfficial
- Peking UniversityOfficial
- Peking UniversityOfficial
- Henan Medical UniversityOfficial
- Dalian Medical UniversityOfficial
- Zhejiang UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.